Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
A Japanese health ministry panel on May 28 agreed to adopt “descendent lineages of the JN.1 strain” for the antigen composition of the COVID-19 vaccine to be used in the national immunization program in the 2025/2026 season. The decision was…
To read the full story
Related Article
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan
September 24, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- Japan Approves Pfizer/BioNTech’s LP.8.1-Tailored COVID Vaccines
August 12, 2025
- Japan Approves Updated Spikevax for LP.8.1 Omicron Strain
August 6, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
- Moderna Files Updated Spikevax for LP.8.1 Strain in Japan
June 9, 2025
REGULATORY
- MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
- MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
- MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…